» Articles » PMID: 25834404

Human Colon Carcinogenesis is Associated with Increased Interleukin-17-driven Inflammatory Responses

Overview
Specialty Pharmacology
Date 2015 Apr 3
PMID 25834404
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammation is known to contribute to carcinogenesis in human colorectal cancer. Proinflammatory cytokine interleukin-17 (IL-17 or IL-17A) has been shown to play a critical role in colon carcinogenesis in mouse models. However, few studies have investigated IL-17A in human colon tissues. In the present study, we assessed IL-17-driven inflammatory responses in 17 cases of human colon adenocarcinomas, 16 cases of human normal colon tissues adjacent to the resected colon adenocarcinomas, ten cases of human ulcerative colitis tissues from biopsies, and eight cases of human colon polyps diagnosed as benign adenomas. We found that human colon adenocarcinomas contained the highest levels of IL-17A cytokine, which was significantly higher than the IL-17A levels in the adenomas, ulcerative colitis, and normal colon tissues (P<0.01). The levels of IL-17 receptor A (IL-17RA) were also the highest in human colon adenocarcinomas, followed by adenomas and ulcerative colitis. The increased levels of IL-17A and IL-17RA were accompanied with increased IL-17-driven inflammatory responses, including activation of extracellular signal-regulated kinase (ERK)1/2 and c-Jun N-terminal kinase (JNK) pathways, increase in expression of matrix metalloproteinase (MMP)9, MMP7, MMP2, B-cell lymphoma (Bcl-2), and cyclin D1, decrease in Bcl-2-associated X protein (BAX) expression, and increase in vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) expression that were associated with increased angiogenesis. These findings suggest that IL-17 and its signaling pathways appear as promising new targets in the design and development of drugs for cancer prevention and treatment, particularly in colorectal cancer.

Citing Articles

A Review of the Use of Native and Engineered Probiotics for Colorectal Cancer Therapy.

Han H, Zhang Y, Tang H, Zhou T, Khan A Int J Mol Sci. 2024; 25(7).

PMID: 38612706 PMC: 11011422. DOI: 10.3390/ijms25073896.


Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions.

He R, Huang S, Lu J, Su L, Gao X, Chi H Front Immunol. 2024; 15:1362709.

PMID: 38415252 PMC: 10897008. DOI: 10.3389/fimmu.2024.1362709.


Elevated profiles of peripheral Th22, Th17, Th2 cells, and decreased percentage of Th1 cells in breast cancer patients.

Peng Z, Dong X, He M, Zhao Y, Liu Y, Li M Thorac Cancer. 2023; 14(33):3282-3294.

PMID: 37732365 PMC: 10665788. DOI: 10.1111/1759-7714.15119.


Do Elevated YKL-40 Levels Drive the Immunosuppressive Tumor Microenvironment in Colorectal Cancer? Assessment of the Association of the Expression of YKL-40, MMP-8, IL17A, and PD-L1 with Coexisting Type 2 Diabetes, Obesity, and Active Smoking.

Ochman B, Mielcarska S, Kula A, Dawidowicz M, Robotycka J, Piecuch J Curr Issues Mol Biol. 2023; 45(4):2781-2797.

PMID: 37185706 PMC: 10136442. DOI: 10.3390/cimb45040182.


Protective Effect of Qingchang Wenzhong Decoction on Colitis and Colitis-Related Carcinogenesis by Regulating Inflammation and Intestinal Fibrosis.

Cheng Y, Li J, Zhang X, Li Y, Shi X, Shi R J Inflamm Res. 2023; 16:1479-1495.

PMID: 37056910 PMC: 10089279. DOI: 10.2147/JIR.S402395.


References
1.
Li J, Lau G, Chen L, Dong S, Lan H, Huang X . Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One. 2011; 6(7):e21816. PMC: 3131399. DOI: 10.1371/journal.pone.0021816. View

2.
Solt L, Kumar N, Nuhant P, Wang Y, Lauer J, Liu J . Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 2011; 472(7344):491-4. PMC: 3148894. DOI: 10.1038/nature10075. View

3.
Zhu S, Pan W, Song X, Liu Y, Shao X, Tang Y . The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α. Nat Med. 2012; 18(7):1077-86. DOI: 10.1038/nm.2815. View

4.
Schmidt E, Larsen H, Kristensen N, Poulsen S, Pedersen A, Claesson M . TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. Inflamm Bowel Dis. 2013; 19(8):1567-76. DOI: 10.1097/MIB.0b013e318286fa1c. View

5.
Holtta V, Klemetti P, Salo H, Koivusalo A, Pakarinen M, Westerholm-Ormio M . Interleukin-17 immunity in pediatric Crohn disease and ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013; 57(3):287-92. DOI: 10.1097/MPG.0b013e3182979252. View